Fighting the Zika virus with the power of supercomputing

Rutgers is taking a leading role in an IBM-sponsored World Community Grid project that will use supercomputing power to identify potential drug candidates to cure the Zika virus. The project, known as OpenZika, employs a global team of scientists who will perform "virtual" experiments in a search of treatments for the fast-spreading virus that the World Health Organization has declared a global public health emergency.

OpenZika will screen current drugs and millions of drug-like compounds from existing databases against models of Zika protein structures (and also against structures of proteins from related viruses, including West Nile Virus and Dengue). These computational results will be shared quickly with the research community and general public, with compounds showing the most promise then tested in laboratory settings.

"Instead of having to wait a number of years, even decades potentially, to test all these compounds in order to find a few that could form the basis of antiviral drugs to cure Zika, we will perform these initial tests in a matter of months, just by using idle computing power that would otherwise go to waste," says Alex Perryman, a research teaching specialist at Rutgers' New Jersey Medical School, in Professor Joel Freundlich's lab. Perryman was selected as co-principal investigator of the OpenZika project, while Freundlich serves as a key consultant.

IBM created World Community Grid in 2004 to address researchers' critical need for supercomputing power. Partially hosted on IBM's SoftLayer cloud technology, World Community Grid provides massive amounts of supercomputing power to scientists for free by harnessing the unused computing power of volunteers' computers and Android devices.

IBM and the scientific team are seeking volunteers with a computer or Android device to join the OpenZika project. The volunteers, who can sign up on the World Community Grid website, need not have a particular expertise. Nor are there financial obligations or time commitments. All participants need to do is run an app on their Windows, Mac, Linux or Android devices that automatically performs virtual experiments whenever their machines are idle.

More than three million computers and mobile devices used by nearly 750,000 people and 470 institutions across 80 countries have combined to create World Community Grid, which makes it one of the largest supercomputers on the planet. These volunteers have contributed supercomputing power for more than two dozen World Community Grid projects over the past 11 years, at an estimated value of more than $500 million.

Rutgers' Perryman has had deep experience working with IBM's World Community Grid. From 2007 to 2013, he managed and performed the day-to-day duties required for FightAIDS@Home, the first biomedical computing project on World Community Grid. In 2011, Perryman designed, developed and ran the grid's Global Online Fight Against Malaria (GO FAM) project, which has resulted in identifying promising tool compounds for treating malaria and drug-resistant tuberculosis.

In less than two years, GO FAM volunteers on the grid performed more than a billion docking jobs, which, Perryman estimates, would have taken at least 100 years using the computer capacity found at most universities. The Freundlich lab has leveraged GO FAM data against tuberculosis drug targets, along with novel machine learning techniques they have developed, to seed novel therapeutic strategies.

In addition to Perryman's GO FAM project, World Community Grid has helped researchers identify new potential treatments for childhood cancer, test materials for more efficient solar cells, and study how nanotechnology can filter water more efficiently.

For the OpenZika project IBM is working with an international team of researchers, led by Federal University of Goias in Brazil; with scientists from the Oswaldo Cruz Foundation (Fiocruz) in Brazil; Rutgers University's New Jersey Medical School (NJMS); and the University of California, San Diego (UCSD). Carolina Horta Andrade, professor at Federal University of Goias, is the principal investigator. Joining Perryman as co-PI is Sean Ekins, CEO, Collaborations Pharmaceuticals.

Volunteers can support the OpenZika search for a cure by joining World Community Grid. IBM also invites researchers to submit research project proposals to receive this free resource. For more information about IBM's philanthropic efforts, visit http://www.citizenIBM.com.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...